Strategic Product Portfolio Management in the Pharmaceutical Industry: Market Intelligence, Regulatory Insight, and Stage-Gate Decision-Making

Product Portfolio Management (PPM) is the strategic function within pharmaceutical organizations responsible for identifying, evaluating, and prioritizing products for development across Active Pharmaceutical Ingredient (API) and finished-dosage-formulation businesses. This review synthesizes the key parameters that guide pharmaceutical product selection—market volume, sales value, growth potential, competitive landscape, patent expiry, regulatory pathway, and manufacturing feasibility—and examines the commercial and regulatory intelligence platforms, such as IQVIA, Cortellis, and the FDA Orange Book, that inform these decisions. Particular attention is given to the structured stage-gate review process comprising the Project Initiation Form, Project Review Form, Project Completion Form, and Project Termination Form, which enables cross-functional teams to make evidence-based go/no-go decisions at defined milestones throughout the product life cycle. The review also considers dosage-form diversification as a portfolio strategy and the collaborative relationship between Portfolio Management and the Intellectual Property, Regulatory Affairs, Research & Development, and Project Management functions. The review concludes that disciplined, data-driven portfolio management is central to building a sustainable and commercially viable pharmaceutical product pipeline.